Novartis's Herrling gets place on WHO panel despite conflicts of interest
This article was originally published in Scrip
Professor Paul Herrling, head of corporate research at Novartis, will sit on a World Health Organization panel tasked to solve financing of R&D into diseases affecting poor countries despite have a direct conflict of interest. The decision by the World Health Organization's executive board was made on 21 January, despite protests from some developing countries and nine NGOs, including Knowledge Ecology International, Oxfam, MSF and Health Action International (scripintelligence.com, 19 January 2010).
You may also be interested in...
The US Food and Drug Administration recently signalled its desire to work more closely with other drug regulators in assessing the quality of pharmaceutical manufacturing facilities around the world.
It seems as if the US FDA is softening its stance on assessing the quality of pharmaceutical manufacturing facilities around the world in future, with an apparent desire to work more closely with other drug regulators. However, incorporating the regulators from countries such as India, China and Japan into a global inspectorate still looks problematical.
Large pharmaceutical companies and Médecins sans Frontières may not often see eye-to-eye over access to medicines in poor countries. But it seems as if industry and the humanitarian body, a prominent critic, do agree that competition works in improving access to vaccines, even though they don't agree about the mechanisms of price setting.